Celgene revenue was $15.28 b in FY, 2018

## Founding Date | 1986 |

Celgene is a subsidiary of Bristol-Myers Squibb

USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 3.6b | 4.8b | 5.5b | 6.5b | 7.7b | 9.3b | 11.2b | 13.0b | 15.3b |

| 18% | 21% | 21% | ||||||

## Cost of goods sold | 306.5m | 425.9m | 299.1m | 340.4m | 385.9m | 420.1m | 438.0m | 461.0m | 587.0m |

## Gross profit | 3.3b | 4.4b | 5.2b | 6.2b | 7.3b | 8.8b | 10.8b | 12.5b | 14.7b |

| 92% | 91% | 95% | 95% | 95% | 95% | 96% | 96% | 96% |

## R&D expense | 121.2m | 1.6b | 1.7b | 5.9b | 5.7b | ||||

## General and administrative expense | 950.6m | 1.2b | 1.4b | 2.9b | 3.3b | ||||

## Operating expense total | 2.2b | 2.8b | 3.3b | 7.8b | 9.5b | ||||

## EBIT | 989.6m | 1.4b | 1.7b | 1.8b | 2.5b | 2.3b | 3.2b | 4.7b | 5.2b |

| 27% | 30% | 32% | 28% | 33% | 24% | 28% | 36% | 34% |

## Interest expense | 12.6m | 42.7m | 63.2m | 91.6m | 176.1m | 310.6m | 500.1m | ||

## Interest income | 44.8m | 25.9m | 15.3m | 105.0m | 45.0m | ||||

## Investment income | (1.9m) | (2.8m) | |||||||

## Pre tax profit | 1.4b | 1.7b | 1.7b | 2.3b | 2.0b | 2.4b | 4.3b | 4.8b | |

## Income tax expense | 132.4m | 102.1m | 225.3m | 215.5m | 327.5m | 421.5m | 373.3m | 1.4b | 786.0m |

## Net Income | 880.5m | 1.3b | 1.5b | 1.4b | 2.0b | 1.6b | 2.0b | 2.9b | 4.0b |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Cash | 1.4b | 1.9b | 2.1b | 3.2b | 4.1b | 4.9b | 6.2b | 7.0b | 4.2b |

## Accounts Receivable | 706.4m | 945.5m | 960.5m | 1.9b | 2.1b | ||||

## Prepaid Expenses | 275.0m | 395.1m | 320.2m | 388.0m | 501.0m | ||||

## Inventories | 260.1m | 189.6m | 259.5m | 340.4m | 393.1m | 443.4m | 497.9m | 541.0m | 458.0m |

## Current Assets | 4.3b | 4.4b | 5.5b | 7.6b | 9.7b | 9.4b | 10.9b | 14.9b | 9.1b |

## PP&E | 509.9m | 506.0m | 578.4m | 593.4m | 642.6m | 814.1m | 929.8m | 1.1b | 1.4b |

## Goodwill | 1.9b | 1.9b | 2.0b | 2.0b | 2.2b | 4.9b | 4.9b | 4.9b | |

## Total Assets | 10.2b | 10.0b | 11.7b | 13.4b | 17.3b | 27.1b | 28.1b | 30.1b | 35.5b |

## Accounts Payable | 94.5m | 121.5m | 145.7m | 156.2m | 198.2m | 240.8m | 247.1m | 305.0m | 418.0m |

## Short-term debt | 392.4m | 526.7m | 308.5m | 544.8m | 605.9m | 500.7m | 501.0m | ||

## Current Liabilities | 1.1b | 1.5b | 1.7b | 1.9b | 2.1b | 2.0b | 3.0b | 3.0b | 4.1b |

## Long-term debt | 1.2b | 1.3b | 2.8b | 15.8b | 19.8b | ||||

## Total Debt | 1.6b | 1.8b | 3.1b | 544.8m | 605.9m | 500.7m | 15.8b | 501.0m | |

## Total Liabilities | 4.2b | 4.5b | 6.0b | 23.2b | 29.3b | ||||

## Common Stock | 4.8m | 4.9m | 5.0m | 10.0m | 10.0m | ||||

## Preferred Stock | |||||||||

## Additional Paid-in Capital | 6.4b | 6.8b | 7.5b | 8.7b | 9.8b | 11.1b | 12.4b | 13.8b | 15.0b |

## Retained Earnings | 248.3m | 1.6b | 3.0b | 4.5b | 6.5b | 8.1b | 10.1b | 13.1b | 17.6b |

## Total Equity | 6.0b | 5.5b | 5.7b | 5.6b | 6.5b | 5.9b | 6.6b | 287.0m | (50.0m) |

## Debt to Equity Ratio | 0.1 x | 0.1 x | 0.1 x | -10 x | |||||

## Debt to Assets Ratio | 0 x | 0 x | 0 x | 0 x | |||||

## Financial Leverage | 1.7 x | 1.8 x | 2.1 x | 2.4 x | 2.7 x | 4.6 x | 4.3 x | 105 x | -709.6 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 880.5m | 1.3b | 1.5b | 1.4b | 2.0b | 1.6b | 2.0b | 2.9b | 4.0b |

## Depreciation and Amortization | 54.2m | 71.2m | 84.9m | 471.0m | 635.0m | ||||

## Accounts Receivable | (234.5m) | (263.1m) | (30.1m) | (101.4m) | (166.3m) | (304.7m) | (222.4m) | (236.0m) | (178.0m) |

## Inventories | 18.7m | 71.0m | (69.7m) | (89.7m) | (56.5m) | (50.6m) | (55.3m) | (42.0m) | 82.0m |

## Accounts Payable | 51.6m | 223.8m | 68.2m | 273.0m | 290.0m | ||||

## Cash From Operating Activities | 1.2b | 1.8b | 2.0b | 2.2b | 2.8b | 2.5b | 4.0b | 5.2b | 5.2b |

## Purchases of PP&E | (98.6m) | (132.1m) | (111.5m) | (279.0m) | (330.0m) | ||||

## Capital Expenditures | (119.7m) | (150.3m) | (286.3m) | (236.2m) | |||||

## Cash From Investing Activities | (2.1b) | 377.7m | (1.6b) | (528.6m) | (1.4b) | (6.3b) | (1.0b) | (2.9b) | (6.4b) |

## Short-term Borrowings | (1.4b) | (4.7b) | (5.7b) | ||||||

## Long-term Borrowings | (513.9m) | (1.9b) | |||||||

## Cash From Financing Activities | 1.2b | (1.7b) | (248.7m) | (553.7m) | (417.4m) | 4.6b | (1.6b) | (1.6b) | (1.5b) |

## Net Change in Cash | 249.0m | 508.3m | 230.9m | 843.0m | (2.8b) | ||||

## Interest Paid | 1.8m | 2.3m | 48.4m | 90.8m | 196.2m | 243.3m | 527.2m | 539.0m | 689.0m |

## Income Taxes Paid | 122.0m | 93.0m | 469.6m | 291.9m | 294.6m | 361.1m | 373.0m | 475.0m | 1.2b |

## Free Cash Flow | 2.3b | 3.0b | 2.8b | 4.2b |

- Source: SEC Filings

- Source: SEC Filings

USD | Q1, 2010 |
---|---|

## Financial Leverage | 1.3 x |

FY, 2016 | |
---|---|

## Active Clinical Studies | 52 |